T1	total-participants 133 156	One hundred and sixteen
T2	eligibility 157 203	women with measurable metastatic breast cancer
T3	age 412 425	over 65 years
T4	total-participants 939 961	One hundred and eleven
T5	total-participants 1003 1006	106
T6	intervention 58 89	pegylated liposomal doxorubicin
T7	outcome 1102 1124	achieving a DI of >90%
T8	iv-bin-abs 1093 1095	37
T9	iv-bin-percent 1097 1100	69%
T10	cv-bin-abs 1173 1175	37
T11	cv-bin-percent 1177 1180	65%
T12	outcome 1290 1299	Mucositis
T13	iv-bin-percent 1348 1351	35%
T14	cv-bin-percent 1376 1379	14%
T15	outcome 1394 1433	palmar plantar erythrodysesthesia (PPE)
T16	iv-bin-percent 1484 1486	2%
T17	cv-bin-percent 1511 1514	16%
T18	outcome 1536 1563	objective partial responses
T19	iv-bin-abs 1614 1616	15
T20	intervention-participants 1617 1619	51
T21	iv-bin-percent 1621 1624	29%
T22	cv-bin-abs 1639 1641	17
T23	control-participants 1642 1644	56
T24	cv-bin-percent 1646 1649	31%
T25	outcome 1219 1232	adverse event
T26	control 381 386	ARM B
